Our data confirmed that the POU6F2-AS2/miR-125b-5p/E2F transcription factor 3 (E2F3) axis plays a major role in NSCLC progression, suggesting that it can be a therapeutic target for managing NSCLC. Here, E2F3 is linked to non-small cell lung carcinoma.